Jiangsu Hengrui Pharmaceuticals (600276.SH): HRS-8364 tablets approved for clinical trials.
Hengrui Medicine (600276.SH) announcement, the company has received the approval and issuance of the National Medical Products Administration on HRS-...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has received approval from the National Medical Products Administration to conduct clinical trials for HRS-8364 tablets. HRS-8364 is an innovative anti-tumor drug developed independently by the company, intended for the treatment of advanced solid tumors.
Related Articles
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
